Trial Profile

Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Adrenocortical carcinoma; Carcinoma; Cervical cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Neuroendocrine carcinoma; Ovarian cancer; Paraganglioma; Penile cancer; Phaeochromocytoma; Renal cell carcinoma; Sarcoma; Skin cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Testicular cancer; Thymoma; Thyroid cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

18 May 2023 Planned End Date changed from 20 Dec 2022 to 31 Dec 2025.
18 May 2023 Planned primary completion date changed from 20 Dec 2022 to 31 Dec 2025.
20 Apr 2022 Planned End Date changed from 20 Dec 2021 to 20 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com